Finally, the findings of this study showed that targeting liver TXNIP by quercetin and allopurinol may be a therapeutic target in the prevention of type 1 diabetes-associated NAFLD [28]. Here, TXNIP is linked to metabolic dysfunction-associated steatotic liver disease.